Drug Profile
Polmacoxib - CrystalGenomics
Alternative Names: Acelex; CG-100649; CG100650; CG1801; CGL1802Latest Information Update: 17 May 2022
Price :
$50
*
At a glance
- Originator CrystalGenomics
- Class Antirheumatics; Benzene derivatives; Fluorobenzenes; Furans; Nonsteroidal anti-inflammatories; Small molecules; Sulfonamides
- Mechanism of Action Carbonic anhydrase inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Marketed Osteoarthritis
Most Recent Events
- 19 May 2020 CrystalGenomics completes a phase I trial in Healthy volunteers in South Korea (NCT05370716)
- 11 Nov 2019 CrystalGenomics initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT05370716)
- 03 May 2019 CrystalGenomics completes a phase I trial (In volunteers) in South Korea (NCT03774355)